For Healthcare Providers

Right treatment. Right time. Right place.

GammaTile Therapy is a Surgically Targeted Radiation Therapy 

(STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local

recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.[1]




Outcomes & Safety

GammaTile Therapy extends local recurrence-free survival vs previous standard of care treatment.[1]

  • Significantly improves outcomes by approximately 2X
    across all tumor types in the study

    • Median time to same-site recurrence was 19.9 months, a 9.7-month improvement across all tumor types[1]



Median local control (LC) after GammaTile Therapy vs prior treatment was 12.0 vs 9.5 months for high-grade glioma (HGG) patients (HR 0.6, p = .13) and 48.8 vs 23.3 months (HR 0.24, p = .01) for meningioma patients. For the metastasis patients, the median LC has not been reached vs 5.1 months with prior treatment (HR .07, p = 0.02).[1]  The median overall survival (OS) was 12.0 months for HGG patients, 12.0 months for the brain metastasis patients, and 49.2 months for the meningioma patients.[1]


Excellent safety profile: comparable to or better than currently available treatments[1,4-8,*]

*Defined as common terminology criteria for adverse events (CTCAE), Grade 3–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

GammaTile Therapy is a safe and effective, Surgically Targeted Radiation Therapy (STaRT) for patients with recurrent brain tumors[1]
  • Extends local recurrence-free survival with minimal complications[1]

  • Reduces patient burden and preserves quality of life[1]

  • Facilitates favorable reimbursement (CMS craniotomy code ICD-10 MS-DRG 023)

Clinical efficacy, immediacy, and efficiency 

  • Enables immediate treatment at resection with no additional hospital stay 

  • Integrates into the surgical workflow for procedural ease and speed

  • Takes approximately 6 minutes to complete tile placement

  • Simplifies care with 100% "built-in" compliance and no special inpatient precautions or contraindications with systemic therapies


How It Works. An Eloquent Solution.

GammaTile Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.[1]


Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment. 

Enhanced local control and optimized efficacy[1]

  • 50% of the therapeutic dose is delivered within the first 
    10 days after surgery, which helps prevent residual tumor cells from replicating[9]

  • 88% of the therapeutic dose is delivered within 30 days, with more than 95% of the dose delivered by 6 weeks[9]

  • A favorable depth-dose profile optimizes local
    tumor control

Bioresorbable, conformable collagen tile preserves healthy tissue 
  • Provides a structural offset of the radiation source from normal brain tissue

  • Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles

  • Minimizes local hot and cold spots

  • Facilitates rapid, accurate placement to deliver a predictable radiation dose

By implanting [GammaTile] directly at surgery, you are treating the tumor immediately. She’s getting much more radiation in the area she needs it the most.

Dr Clark Chen

Professor, Lyle French Chair in Neurosurgery, and Department Head

University of Minnesota


GammaTile Therapy Webinar

Watch an in-depth educational webinar about GammaTile Therapy, presented by world-renowned neurosurgeon, Dr. Joseph Zabramski and hosted by The Musella Foundation. Content includes background, safety and efficacy, surgical placement, a case study, and clinical trial information. Watch the GammaTile Therapy Webinar


Notable Clinical Publications & Awards

Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. David G. Brachman, MD, Emad Youssef, MD, Christopher J. Dardis, MD, Nader Sanai, MD, Joseph M. Zabramski, MD, Kris A. Smith, MD, Andrew S. Little, MD, Andrew G. Shetter, MD, Theresa Thomas, MS, Heyoung L. McBride, MD, MS, Stephen Sorensen, PhD, Robert F. Spetzler, MD, and Peter Nakaji, MDl, in the Journal of Neurosurgery. 2018:1-10. doi:10.3171/2018.7.jns18656

Rosenblum-Mahaley Clinical Research Award winner for best abstract in field of neuro-oncology for Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. AANS Annual Meeting 2019

Judith Stitt Best Abstract Award winner for Surgically targeted radiation therapy: safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. ABS Annual Meeting 2019

RTHP-32. First experience with gamma tile permanent implants for recurrent brain tumors. Clara Ferreira, Parham Alaei, Clark Chen, Margaret Reynolds, David Sterling, Kathryn Dusenbery, Neuro-Oncology. Volume 21, Issue Supplement_6, November 2019, Page vi216, doi:10.1093/neuonc/noz175.903


  1. Nakaji P, Youssef E, Dardis C, Smith K, Pinnaduwage D, Brachman D. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Poster presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

  2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Euro J Cancer. 2012;48:2192-2202. 

  3. Shi W, Bryan MS, Gilbert MR, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiation Oncol Biol Phys. 2018;100(1):38-44. 

  4. Lin AJ, Hui C, Dahiya S, et al. Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation. Int J Radiation Oncol Biol Phys. 2018;102(1):194-203. 

  5. Scossianti S, Franncolini G, Carta G, et al. Re-irradiation as salvage in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncology. 2018;126:89-91.

  6. Combs SE, Debus J, Schulz-Ertner D. Radiotheraputic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167. 

  7. Wernicke AG, Smith AW, Taube S, et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurg. 2017;126(4):1212-1219. 

  8. Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical resection and interstitial iodine-125 brachytherapy for high-grade meningiomas: a 25-year series. Neurosurgery. 2017;80(3):409-416. 

  9. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
    Int J Radiat Oncol Biol Phys. 2003;55(2):378-385. 

  10. Chiu-Tsao ST, Napoli JJ, Davis SD, et al. Dosimetry for 131Cs and 125I seeds in solid water phantom using radiochromic EBT film. Appl Radiat Isot. 2014;92:102-114. 



GammaTile Therapy is indicated to deliver radiation therapy for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms. For full safety information, refer to the instructions for use. 

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2021 GT Medical Technologies, Inc.  I  All rights reserved  |   Instructions for Use  Privacy Policy | Terms of Use